The frequencies of antibody development so far reported in patients treated with different interferons (IFNs) are not readily comparable because of differences in treatment regimens and assay methods. Thus the frequency of neutralizing antibody development was analyzed in a large sample of sera derived from a relatively homogeneous group of patients treated with different IFN-alpha preparations. The frequency of developing neutralizing antibody to IFN varied according to the IFN given. Particularly, the seroconversion frequency was significantly higher in patients treated with recombinant IFN-alpha-2a (20.2%) than in patients treated with either recombinant IFN-alpha-2b (6.9%) or IFN-alpha-N1 (1.2%), a lymphoblastoid IFN-alpha. Furthermore, sera obtained from patients treated with either recombinant IFN neutralized both types of recombinant IFNs but failed to neutralize IFN-alpha-N1.

Neutralizing antibodies to interferon-alpha: relative frequency in patients treated with different interferon preparations / Antonelli, Guido; Currenti, M; Turriziani, Ombretta; Dianzani, F.. - In: THE JOURNAL OF INFECTIOUS DISEASES. - ISSN 0022-1899. - STAMPA. - 163:(1991), pp. 882-885. [10.1093/infdis/163.4.882]

Neutralizing antibodies to interferon-alpha: relative frequency in patients treated with different interferon preparations.

ANTONELLI, Guido;TURRIZIANI, Ombretta;
1991

Abstract

The frequencies of antibody development so far reported in patients treated with different interferons (IFNs) are not readily comparable because of differences in treatment regimens and assay methods. Thus the frequency of neutralizing antibody development was analyzed in a large sample of sera derived from a relatively homogeneous group of patients treated with different IFN-alpha preparations. The frequency of developing neutralizing antibody to IFN varied according to the IFN given. Particularly, the seroconversion frequency was significantly higher in patients treated with recombinant IFN-alpha-2a (20.2%) than in patients treated with either recombinant IFN-alpha-2b (6.9%) or IFN-alpha-N1 (1.2%), a lymphoblastoid IFN-alpha. Furthermore, sera obtained from patients treated with either recombinant IFN neutralized both types of recombinant IFNs but failed to neutralize IFN-alpha-N1.
1991
01 Pubblicazione su rivista::01a Articolo in rivista
Neutralizing antibodies to interferon-alpha: relative frequency in patients treated with different interferon preparations / Antonelli, Guido; Currenti, M; Turriziani, Ombretta; Dianzani, F.. - In: THE JOURNAL OF INFECTIOUS DISEASES. - ISSN 0022-1899. - STAMPA. - 163:(1991), pp. 882-885. [10.1093/infdis/163.4.882]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/451990
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 22
  • Scopus 197
  • ???jsp.display-item.citation.isi??? 204
social impact